MHLW Report Finds No Relations Between Tamiflu Use And Abnormal Behavior
This article was originally published in PharmAsia News
Executive Summary
A safety team at Japan's Ministry of Health, Labor and Welfare reported June 17 that clinical tests found no evidence that taking Chugai Pharmaceutical's flu drug Tamiflu (oseltamivir phosphate) affected electrocardiograms and sleep patterns. The clinical report also stated that there was no evidence showing relation between the administration of Tamiflu and sudden death or abnormal behavior. The team conducted electrocardiograms on 11 healthy males between the ages of 20-51. The team also conducted researches on brain waves of 31 males aged between 20-24 when sleeping and found no abnormality in brain waves after taking Tamiflu. (Click here for more - Japanese language
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.